BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Ocugen, Union Pacific

Reuters
2025/09/15
BUZZ-U.S. STOCKS ON THE MOVE-<a href="https://laohu8.com/S/TSLA">Tesla</a>, <a href="https://laohu8.com/S/OCGN">Ocugen</a>, Union Pacific

Eikon search string for individual stock moves: STXBZ

The Day Ahead newsletter: https://refini.tv/3LI4BU7

The Morning News Call newsletter: https://refini.tv/3dKUyB8

U.S. stock index futures were muted on Monday, setting a cautious tone for a crucial week in which the Federal Reserve is widely expected to resume its interest rate cutting cycle, while Tesla rose after CEO Elon Musk's share purchase. .N

** Alibaba.com Ltd <BABA.N>:

** Trip.com Group Ltd <TCOM.O>:

BUZZ - HK shares at nearly 4-year peak on sector outlook optimism nL2N3V203L

** Nvidia Corp <NVDA.O>:BUZZ - Falls after China says it violated anti-monopoly law nL3N3V20EP

** Timken Co <TKR.N>:BUZZ - JPM initiates Timken at 'neutral', seeing balanced near-term risk and reward nL3N3V20FY

** Phillips 66 <PSX.N>:BUZZ - Jefferies raises PT on Phillips 66 over deal with Cenovus Energy nL3N3V20GQ

** NextDecade Corp <NEXT.O>:BUZZ - TD Cowen cuts NextDecade to 'hold' on financing, margin risks nL3N3V20GV

** Avita Medical Inc <RCEL.O>:BUZZ - Climbs after European nod for wound care device nL3N3V20I6

** Hims & Hers Health Inc <HIMS.N>:BUZZ - Down after US FDA chief says super bowl ad violated drug promotion rules nL3N3V20I5

** Tesla Inc <TSLA.O>:BUZZ - Jumps as Musk buys 2.57 million shares nL3N3V20IJ

** Eversource Energy <ES.N>:BUZZ - Jefferies raises PT on Eversource Energy, retains 'underperform' rating nL3N3V20HM

** Ocugen Inc <OCGN.O>:BUZZ - Up after licensing deal for ophthalmic gene therapy in South Korea nL3N3V20J5

** Permian Resources Corp <PR.N>:BUZZ - Slips after launching secondary offering nL6N3V20CG

** VF Corp <VFC.N>:BUZZ - To sell Dickies for $600 million, shares rise nL6N3V20CX

** Union Pacific Corp <UNP.N>:BUZZ - Shares rise after Citigroup hikes rating to 'buy' nL3N3V20K6

** Monte Rosa Therapeutics Inc <GLUE.O>:BUZZ - Soars after $5.7 billion drug development deal with Novartis nL3N3V20KM

(Compiled by Rajarshi Roy and Sahil Pandey)

((Sahil.Pandey@thomsonreuters.com))

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10